Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) von Pestalozzi, B.C., Zahrieh, D., Price, K.N., Holmberg, S.B., Lindtner, J., Collins, J., Crivellari, D., Fey, M.F., Murray, E., Pagani, O., Simoncini, E., Castiglione-Gertsch, M., Gelber, R.D., Coates, A.S., Goldhirsch, A.

Volltext

Transarterial Chemoembolization as a Bridge to Liver Transplantation for Hepatocellular Carcinoma: An Evidence‐Based Analysis von Lesurtel, M., Müllhaupt, B., Pestalozzi, B. C., Pfammatter, T., Clavien, P.‐A.

Volltext

Trastuzumab in CSF von Pestalozzi, B C, Brignoli, S

Volltext

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting von Matter-Walstra, K., Braun, R., Kolb, C., Ademi, Z., Dummer, R., Pestalozzi, B.C., Schwenkglenks, M.

Volltext

Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02) von Ruhstaller, T., Widmer, L., Schuller, J.C., Roth, A., Hess, V., Mingrone, W., von Moos, R., Borner, M., Pestalozzi, B.C., BalmerMajno, S., Köberle, D., Terraciano, L., Schnider, A., Bodis, S., Popescu, R.

Volltext

Brain metastases and subtypes of breast cancer von Pestalozzi, B.C.

Volltext

Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up von Pestalozzi, B., Castiglione, M.

Volltext

Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up von Pestalozzi, B

Volltext

Choice of first line systemic treatment in pancreatic cancer among national experts von Glatzer, M., Horber, D., Montemurro, M., Winterhalder, R., Inauen, R., Berger, M.D., Pestalozzi, B., Pederiva, S., Pless, M., Putora, P.M.

Volltext

Trastuzumab beyond progression: a cost-utility analysis von Matter-Walstra, K.W., Dedes, K.J., Schwenkglenks, M., Brauchli, P., Szucs, T.D., Pestalozzi, B.C.

Volltext

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99 von Pagani, O., Klingbiel, D., Ruhstaller, T., Nolè, F., Eppenberger, S., Oehlschlegel, C., Bernhard, J., Brauchli, P., Hess, D., Mamot, C., Munzone, E., Pestalozzi, B., Rabaglio, M., Aebi, S., Ribi, K., Rochlitz, C., Rothgiesser, K., Thürlimann, B., von Moos, R., Zaman, K., Goldhirsch, A.

Volltext

Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors von Matter-Walstra, K., Braun, R., Kolb, C., Ademi, Z., Dummer, R., Pestalozzi, B.C., Schwenkglenks, M.

Volltext

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cance... von Borner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., Ruhstaller, T., Roth, A., Kappeler, A., Dietrich, D., Lanz, D., Mingrone, W.

Volltext

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09) von Matter‐Walstra, K.W., Achermann, R., Rapold, R., Klingbiel, D., Bordoni, A., Dehler, S., Konzelmann, I., Mousavi, M., Clough‐Gorr, K.M., Szucs, T., Schwenkglenks, M., Pestalozzi, B.C.

Volltext

The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas von Rogers, S.J., Datta, N.R., Puric, E., Timm, O., Marder, D., Khan, S., Mamot, C., Knuchel, J., Siebenhüner, A., Pestalozzi, B., Guckenberger, M., Bodis, S., Riesterer, O.

Volltext

Critical evaluation of the different staging systems for hepatocellular carcinoma von Wildi, S., Pestalozzi, B. C., McCormack, L., Clavien, P.-A.

Volltext

Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design von Eiermann, W, Bergh, J, Cardoso, F, Conte, P, Crown, J, Curtin, N.J, Gligorov, J, Gusterson, B, Joensuu, H, Linderholm, B.K, Martin, M, Penault-Llorca, F, Pestalozzi, B.C, Razis, E, Sotiriou, C, Tjulandin, S, Viale, G

Volltext

ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer von Pestalozzi, B.C., Luporsi-Gely, E., Jost, L.M., Bergh, J.

Volltext

The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate von Goerres, G W, Stupp, R, Barghouth, G, Hany, T F, Pestalozzi, B, Dizendorf, E, Schnyder, P, Luthi, F, von Schulthess, G K, Leyvraz, S

Volltext

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-... von Pestalozzi, B.C., Francis, P., Quinaux, E., Dolci, S., Azambuja, E., Gelber, R.D., Viale, G., Balil, A., Andersson, M., Nordenskjöld, B., Gnant, M., Gutierrez, J., Láng, I., Crown, J.P.A., Piccart-Gebhart, M.

Volltext